Get the Stockscreener App
0.5991
0.15%
-0.0009
After Hours:
.61
0.0109
+1.82%
Quoin Pharmaceuticals Ltd Adr stock is traded at $0.5991, with a volume of 33,722.
It is down -0.15% in the last 24 hours and down -25.85% over the past month.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
See More
Previous Close:
$0.60
Open:
$0.61
24h Volume:
33,722
Relative Volume:
0.01
Market Cap:
$3.00M
Revenue:
-
Net Income/Loss:
$-8.28M
P/E Ratio:
-0.013
EPS:
-45.9343
Net Cash Flow:
$-7.99M
1W Performance:
-4.24%
1M Performance:
-25.85%
6M Performance:
-19.04%
1Y Performance:
-86.69%
1-Day Range:
$0.593
$0.6234
1-Week Range:
$0.585
$0.65
52-Week Range:
$0.4772
$6.18
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd Adr
Sector
Industry
Phone
97299741444
Address
23 HATA'AS STREET, KFAR SABA
Compare QNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
0.5991 | 3.00M | 0 | -8.28M | -7.99M | -45.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Latest News
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results - Yahoo Finance
Quoin Pharmaceuticals advances Netherton syndrome treatment trial - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com India
Quoin Pharmaceuticals expands UK clinical trials for rare disease - Investing.com
Quoin Pharmaceuticals sets date for 2024 shareholder meeting - Investing.com
Balance Sheet Insights: Quoin Pharmaceuticals Ltd ADR (QNRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Quoin Pharmaceuticals CFO buys shares worth over $23,000 - Investing.com
Healthy Upside Potential: Quoin Pharmaceuticals Ltd ADR (QNRX) - SETE News
A closer look at QNRX’s price-to-free cash flow ratio - US Post News
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
Quoin Pharmaceuticals CEO acquires shares worth over $28k - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Quotes, Forecast and News Summary - Benzinga
QNRX Stock Hits 52-Week Low at $0.57 Amid Market Challenges - Investing.com Australia
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference - GlobeNewswire Inc.
Quoin Pharmaceuticals partners with UCC for drug delivery tech By Investing.com - Investing.com
Quoin Pharmaceuticals director Dennis Langer sells shares worth $217 - Investing.com India
Quoin Pharmaceuticals director Dennis Langer sells shares worth $217 By Investing.com - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
GLMD Stock Quote Price and Forecast - CNN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.04% - Investing.com India
Major Indexes Muted Following Strong Jobs Report - Schaeffers Research
Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dunn Gordon | Chief Financial Officer |
Sep 09 '24 |
Buy |
0.79 |
8,856 |
7,005 |
8,856 |
| Carter Denise P. | Chief Operating Officer |
Sep 04 '24 |
Buy |
0.78 |
31,813 |
24,912 |
47,092 |
| Carter Denise P. | Chief Operating Officer |
Sep 03 '24 |
Buy |
0.65 |
5,922 |
3,825 |
15,279 |
| Myers Michael | Chief Executive Officer |
Sep 04 '24 |
Buy |
0.77 |
37,094 |
28,421 |
47,252 |
| Myers Michael | Chief Executive Officer |
Sep 03 '24 |
Buy |
0.62 |
800 |
495 |
10,158 |
| LANGER DENNIS | Director |
Jun 07 '24 |
Sale |
0.73 |
297 |
217 |
53 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):